MedTrace Logo

Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient

NCT00752596 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-02-01

No results posted yet for this study

Summary

This is an open-label, long term compassionate use study of 125 mg per day of azimilide 2HCl in a patient who completed two other protocols (2000098 and 2001060.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

Azimilide 2HCl

One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Stephen R Marcello, MD · Procter and Gamble

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00752596 on ClinicalTrials.gov